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including New York (8 cases), Mas-
sachusetts, Pennsylvania, Connecti-
cut, and Rhode Island (3 cases each) 
(1,2); single cases have been identi-
fied in Michigan, Ohio, North Caro-
lina, Oklahoma, New Jersey, Loui-
siana, Florida, and California (1,2). 
Four other cases have been report-
ed: 3 in South America (Colombia, 
Brazil, Peru) (3,7,8) and 1 in Africa 
(Ethiopia) (9). Only a few Brugia 
species have been identified, includ-
ing B. leporis, found in rabbits in the 
northeastern United States (1,10); B. 
beaveri, found in raccoons and bob-
cats in the southern United States; 
and B. guyanensis, found in coati-
mundi and other vertebrates in South 
America (8). Definitive identifica-
tion with molecular techniques will 
better identify causative species and 
help clarify many of the ecologic and 
epidemiologic questions surrounding 
zoonotic filarial infections.
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To the Editor: We noted the re-
port by Chowdhary et al. (1) and re-
port Candida auris as a causative 
agent of candidemia in South Africa, 
with an estimated prevalence of 0.3% 
(N.P. Govender et al., unpub. data). 
First isolated in 2009, C. auris is an 
emerging species associated with 
clinical disease (2–6). We analyzed 
4 isolates submitted to the National 
Institute for Communicable Diseases 
(Johannesburg, South Africa) from 
4 patients with candidemia who had 
been admitted to different public- and 
private-sector hospitals from October 
2012 through October 2013.
Identification of the isolates was 
undertaken by using ChromAgar 
Candida medium (Mast Diagnos-
tics, Merseyside, UK), Vitek-2 YST 
(bioMérieux, Marcy ľEtoile, France), 
API 20C AUX (bioMérieux), and 
sequencing of internal transcribed 
spacer (ITS) and D1/D2 domains 
of the ribosomal RNA gene (7), fol-
lowed by microbroth dilution suscep-
tibility testing (8). All isolates were 
misidentified as C. haemulonii and 
Rhodotorula glutinis by Vitek-2 YST 
and API 20C AUX assays, respec-
tively (Table).
Similar to the findings of Chow-
dhary et al., all isolates assimilated 
N-acetyl-glucosamine (1). With the 
use of the CBS-KNAW database, 
pairwise sequence alignment of ITS 
region showed 99% sequence homol-
ogy to Kuwait isolates, and alignment 
of D1/D2 domain showed 98% ho-
mology to the Kuwait/India isolates 
(9). In a neighbor-joining phyloge-
netic tree based on ITS sequences, 
South Africa isolates formed a cluster 
with India and Kuwait isolates (online 
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Fluconazole MICs were high for 
all isolates (Table). Isolates 209 and 
224 showed reduced voriconazole 
susceptibility with MICs of 1 µg/mL 
and 2 µg/mL, respectively, which is 
above the epidemiologic cutoff value 
for 11 Candida species (10). Isolates 
were susceptible to amphotericin B 
and echinocandins at low MICs Clini-
cal data were available for 1 patient 
(online Technical Appendix Table). 
Two C. haemulonii isolates were iden-
tified during laboratory-based sentinel 
surveillance for candidemia in South 
Africa; the ITS region of one isolate 
was sequenced and the isolate identi-
fied as C. auris (N.P. Govender, pers. 
comm.). In this study, C. auris was 
misidentified by routinely used tests 
and was accurately identified by se-
quencing, in keeping with previous 
findings (1,3,4,6).
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AMB FLX VRC POS ITC 5FC CAS MFG AFG 
208 85 High-care C. haemulonii Rhodotorula 
glutinis 
C. auris 1 >256 0.5 0.03 0.12 0.12 0.25 0.06 0.25 
209 60 Medical	
ICU 
C. haemulonii R. glutinis C. auris 0.5 >256 1 0.06 0.12 0.12 0.12 0.06 0.12 
224 73 Burn C. haemulonii R. glutinis C. auris 1 >256 2 0.06 0.25 0.12 0.25 0.12 0.25 
293 27 Trauma 
ICU 
C. haemulonii R. glutinis C. auris 1 64 0.25 0.015 0.06 0.06 0.03 0.06 0.06 
*AMB,	amphotericin	B;	FLX,	fluconazole;	VRC,	voriconazole;	POS,	posaconazole;	ITC,	itraconazole;	5FC,	flucytosine;	CAS,	caspofungin;	MFG,	
micafungin;	AFG,	anidulafungin. 
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